Guy Brusselle1, Matthew Germinaro2, Sivan Weiss3, James Zangrilli2. 1. Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. Electronic address: guy.brusselle@uzgent.be. 2. Teva Pharmaceuticals, Frazer, PA, USA. 3. Teva Pharmaceutical Industries Ltd., Netanya, Israel.
Abstract
INTRODUCTION: Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma. METHODS: Data from two 52-week placebo-controlled trials of reslizumab IV 3 mg/kg every 4 weeks in patients aged 12-75 years with inadequately controlled asthma, ≥1 asthma exacerbation within 12 months, and screening blood eosinophils ≥400/μL (NCT01287039/NCT01285323) were stratified by age of asthma onset (<40 or ≥40 years). Annual clinical asthma exacerbation rates, change in lung function, and patient-reported outcomes were analyzed. RESULTS:273 patients with late-onset asthma (placebo, n = 130; reslizumab, n = 143) and 658 with early-onset asthma (placebo, n = 336; reslizumab, n = 322) were included. Baseline demographics were similar between groups. The interaction between age at onset of asthma and effect of reslizumab on asthma exacerbations was statistically significant (p = 0.0083). Compared with placebo, reslizumab produced a 75% relative reduction in asthma exacerbations in patients with late-onset asthma (rate ratio [RR] 0.25; 95% confidence interval [CI], 0.16, 0.40), substantially larger than the reduction in earlier onset patients (RR 0.58; 95% CI, 0.44, 0.76). Similar findings were observed for other measures of asthma, including forced expiratory volume in 1 s (FEV1). The adverse event profile of reslizumab was similar in patients with early- or late-onset asthma. CONCLUSIONS: Compared with placebo, reslizumab produced larger reductions in asthma exacerbations and larger improvements in lung function in patients with late versus early-onset asthma.
RCT Entities:
INTRODUCTION:Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma. METHODS: Data from two 52-week placebo-controlled trials of reslizumab IV 3 mg/kg every 4 weeks in patients aged 12-75 years with inadequately controlled asthma, ≥1 asthma exacerbation within 12 months, and screening blood eosinophils ≥400/μL (NCT01287039/NCT01285323) were stratified by age of asthma onset (<40 or ≥40 years). Annual clinical asthma exacerbation rates, change in lung function, and patient-reported outcomes were analyzed. RESULTS: 273 patients with late-onset asthma (placebo, n = 130; reslizumab, n = 143) and 658 with early-onset asthma (placebo, n = 336; reslizumab, n = 322) were included. Baseline demographics were similar between groups. The interaction between age at onset of asthma and effect of reslizumab on asthma exacerbations was statistically significant (p = 0.0083). Compared with placebo, reslizumab produced a 75% relative reduction in asthma exacerbations in patients with late-onset asthma (rate ratio [RR] 0.25; 95% confidence interval [CI], 0.16, 0.40), substantially larger than the reduction in earlier onset patients (RR 0.58; 95% CI, 0.44, 0.76). Similar findings were observed for other measures of asthma, including forced expiratory volume in 1 s (FEV1). The adverse event profile of reslizumab was similar in patients with early- or late-onset asthma. CONCLUSIONS: Compared with placebo, reslizumab produced larger reductions in asthma exacerbations and larger improvements in lung function in patients with late versus early-onset asthma.
Authors: Manuel A R Ferreira; Riddhima Mathur; Judith M Vonk; Agnieszka Szwajda; Ben Brumpton; Raquel Granell; Bronwyn K Brew; Vilhelmina Ullemar; Yi Lu; Yunxuan Jiang; Patrik K E Magnusson; Robert Karlsson; David A Hinds; Lavinia Paternoster; Gerard H Koppelman; Catarina Almqvist Journal: Am J Hum Genet Date: 2019-03-28 Impact factor: 11.025
Authors: Matthew J Camiolo; Xiaoying Zhou; Timothy B Oriss; Qi Yan; Michael Gorry; William Horne; John B Trudeau; Kathryn Scholl; Wei Chen; Jay K Kolls; Prabir Ray; Florian J Weisel; Nadine M Weisel; Nima Aghaeepour; Kari Nadeau; Sally E Wenzel; Anuradha Ray Journal: Cell Rep Date: 2021-04-13 Impact factor: 9.423